2021 National C. diff Advocacy Summit
Proudly supported by
Speakers
Keynote
Advocate
Booths
Ferring
Microbome Therapeutics Development
Tessa Miller
"What Doesn't Kill You: A Life with Chronic Illness--Lessons in Revolt"
Summit Therapeutics
Currently Recruiting for a Phase 3 C. Diff Treatment Trial
DNV3837, A New Parenteral Treatment for C. difficile Infection
DEINOVE is a French biotech company that uses its lead generation platform to develop innovative anti-infective drugs, is pursuing the Phase II clinical trial of its antibiotic candidate DNV3837.
Antimicrobial Resistance Fighter Coalition
Organizations, leaders and individuals united in their commitment to address the threat and burden of AMR.
Seres
Realizing the possibilities within
Peggy Lillis Foundation Merch
Just launched new merch!